Inclusion Criteria:

- At least 18 years of age

- Diagnosed with localized, prostate cancer and who have been offered curative therapy
(radical prostatectomy; cryotherapy; brachytherapy; EBRT), and refused

- Localized prostate cancer stage T1C up to T2A based on biopsy performed at least 6
weeks prior to enrollment

- Gleason score ≤ 3+3 with ≤50% of sampled cores positive, and each positive core
having a tumour length of ≤5 mm

- PSA < 10 ng/mL

- No prior treatment for prostate cancer

- Signed Informed Consent Form

Exclusion Criteria:

- Any condition or history of illness or surgery that, in the opinion of the
investigator and/or the Sponsor, might confound the results of the study or pose
additional risks to the patient.

- All patients whose current pre-operative cardiac evaluation does not show their
fitness for a procedure requiring general anesthesia;

- Patients with a prior history of viral or alcoholic hepatitis, and other patients
felt to be at risk for hepatotoxicity including concomitant use of potentially
hepatotoxic medications or dietary supplements;

- Patients with a history of inflammatory bowel disease or other factors which may
increase the risk of fistula formation;

- Patients who have received any hormonal manipulation (excluding 5-alpha reductase
inhibitors) or androgen supplements within the previous 6 months;

- Patients previously treated by radiation therapy (external therapy or brachytherapy)
or chemotherapy or any therapy for prostate cancer;

- Patients who have received or are receiving chemotherapy for prostate carcinoma or
other significant cancer;

- Patients who have undergone previous TURP (trans-urethral resection of the prostate);

- Patients with a history of urethral stricture disease

- Patients with a history of acute urinary retention

- Patients who are currently (within 10 days before the treatment procedure) receiving
any medications having potential photosensitizing effects (e.g. tetracyclines,
sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics
and griseofulvin)

- Patients who are currently receiving anticoagulant drugs (within 10 days before the
treatment procedure) (e.g.: coumadin, warfarin)

- Patient who stopped long term treatment of acetylsalicylic acid (aspirin) or other
anti platelets agents within 10 days prior to the treatment procedure;

- Patient suspected of Disseminated Intravascular Coagulation (DIC) as defined by the
presence of three out of the five following criteria: platelets decrease, increase of
PT, increase of aPTT, fibrinogen decrease, D-Dimer increase; from the normal
laboratory ranges;

- Patient with a history of vasculitis or collagen vascular disease;

- History of non compliance with medical therapy and medical recommendations or an
unwillingness or inability to complete patient self-administered questionnaires;

- Participation in a clinical study or receipt of an investigational treatment within
the past 3 months;

- A history of porphyria;

- A history of sun hypersensitivity or photosensitive dermatitis;

- Renal disorders (blood creatinine > 1.5 x ULN) or known post mictional residue >
150cc

- Hepatic disorders (transaminases > ULN, bilirubin > ULN, GGT > ULN). In case of
slight abnormalities, another exam could be performed. If the results are within
normal ranges, then the patient can be included;

- Hematological disorders (white cells < 2500/mm3, neutrophils < 1500/mm3, platelets, <
140.000/mm3, Hb ≤ 10 g/dL);

- Patients with contra-indication to MRI (such as pace maker, metal prosthesis, etc.).